BioCardia, Inc.

Stage 1 · Basing · week 9

As of Oct 22, 2026, BioCardia is in Stage 1, the basing phase, now in week 9 (since Aug 25, 2026). It closed at $0.93, 36.7% below its 52-week high and below its 200-day average, which is falling.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. More about the company

$0.93

-5.33% today

$14.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is BCDA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S4 53w

S4 57w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 15w → S1 10w → S4 53w → S1 9w → S4 4w → S1 2w → S4 5w → S1 2w → S4 57w → S1 8w current

Total tracked: 166 weeks across 10 stage runs.

BCDA among Biotechnology310th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…310	BCDABioCardia, Inc.	Stage 1 · wk 9	29	−11.4%

vs 52W High

-36.7%

$0.77 lo$1.47 hi

36.7% below 52W high, far from high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 9

1w13w26w

Week 9, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-14.7%

200 DMA: $1.09 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.20x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-11.4%

+9.4%

-20.5%

YTD

-26.8%

-37.6%

Scan Membership

Breakout Watch

Latest: 2023-06-28

6 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 9 · Vol 0.20x

2026-10-21S1

Wk 9 · Vol 0.53x

2026-10-20S1

Wk 8 · Vol 0.84x

2026-10-19S1

Wk 8 · Vol 1.78x

2026-10-16S1

Wk 8 · Vol 0.42x

2026-10-15S1

Wk 8 · Vol 0.90x

2026-10-14S1

Wk 8 · Vol 0.53x

2026-10-13S1

Wk 7 · Vol 0.25x

2026-10-12S1

Wk 7 · Vol 0.29x

2026-10-09S1

Wk 7 · Vol 0.37x

2026-10-08S1

Wk 7 · Vol 0.59x

2026-10-07S1

Wk 7 · Vol 0.61x

Moving averages & range

50 DMA

$1.06

200 DMA

$1.09

52W High

$1.47

52W Low

$0.77

5D Low

$0.90

Resistance levels (recent highs)

20d High

$1.09

60d High

$1.25

120d High

$1.25

250d High

$1.47

Next resistance

+17.2%

to 20d High

ROE

-1803.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 5.2

BioCardia: quick answers

What stage is BioCardia in?

As of Oct 22, 2026, BioCardia (BCDA) is in Stage 1, the basing phase. It entered Stage 1 on Aug 25, 2026 and is in week 9. What the four stages mean

Is BioCardia in an uptrend?

Not yet. BioCardia is in Stage 1, a base that can come before an uptrend. It trades 14.7% below its 200-day average, which is falling.

How far is BioCardia from its 52-week high?

BioCardia closed at $0.93 on Oct 22, 2026, 36.7% below its 52-week high of $1.47. Its 52-week low is $0.77.

How has BioCardia performed over the past year?

As of Oct 22, 2026, BioCardia is down 37.6% over the past year and down 26.8% so far in 2026.

Which sector and industry is BioCardia in?

BioCardia is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.